More-EUROPA is excited to announce a major funding milestone, having raised €101,095,479 in its latest round of investment. This crucial capital infusion marks a significant step forward in our mission to harness the power of real world data (RWD) in the realm of drug development, registration, and assessment in Europe. While randomized controlled trials (RCTs) have long been the cornerstone in the drug development landscape, we believe that a more sophisticated harnessing of RWD can provide deeper insights into the effects of medicinal products once they are in real-world settings. Our innovative approach bridges the gap between conventional clinical trials and the growing need for expansive, real-life evidence, catering specifically to the data requirements of regulatory authorities and health technology assessment (HTA) bodies.
This investment will allow us to accelerate our project, which is dedicated to developing, implementing, and establishing rigorous evidentiary standards and methodologies. By doing so, we pave the way for a more efficient and transparent process for understanding drug performance and safety. The funding will support a multi-disciplinary team of experts, advanced data analytics, and state-of-the-art technologies to capitalize on the untapped potential of RWD. Ultimately, our efforts aim to improve patient outcomes and transform the landscape of medicinal product regulation across Europe. As we move forward, we are committed to maintaining the highest levels of scientific integrity and innovation, ensuring that our work not only meets but exceeds the stringent demands of modern drug evaluation. This funding boost is not just an investment in More-EUROPA—it is an investment in the future of healthcare.
.png&w=3840&q=75)
